We evaluated 70 HIV-infected pregnant women with CD4⁺ cell count >350 cells per cubic millimeter who received zidovudine, lamivudine, and nevirapine from week 25 of gestation until 6 months after delivery and a 3-week tail of zidovudine and lamivudine at the moment of drug discontinuation. Forty days after the interruption of all drugs resistance mutations were present in 5 of 70 (7.1%) women. Two of them had the same mutation archived in baseline HIV DNA. The other 3 women had, at least once, detectable viral load and presence of mutations during treatment. Overall, the risk of developing resistance mutations in compliant women was low.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAI.0b013e318220ed92 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir.
Viruses
December 2024
HIV Pathogenesis Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
Islatravir (ISL) is the first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTtI) with novel modes of action. Data on ISL resistance are currently limited, particularly to HIV-1 non-B subtypes. This study aimed to assess prevalent nucleos(t)ide reverse transcriptase inhibitor (NRTI)-resistant mutations in HIV-1 subtype C for their phenotypic resistance to ISL.
View Article and Find Full Text PDFA rare case report of severe aplastic anaemia caused by long-term use of zidovudine.
BMC Infect Dis
December 2024
Department of Pharmacy, Hangzhou Xixi Hospital, Hangzhou, Zhejiang, China.
Background: Zidovudine is an antiviral drug used to treat acquired immune deficiency syndrome (AIDS). Anaemia is a common adverse effect of zidovudine that usually occurs in the first 2 to 4 weeks of initial treatment. Here, we describe a patient with HIV infection who developed severe aplastic anaemia 11 years after taking zidovudine.
View Article and Find Full Text PDFOutcomes of HIV-infected children on antiretroviral therapy for at least 10 years at the Essos Hospital Centre, Cameroon: contributing to the elimination of paediatric AIDS in tropical settings.
J Trop Pediatr
December 2024
African Population and Health Research Centre, Dakar, Dakar 12500, Senegal.
Evidence on long-term outcomes of children receiving antiretroviral therapy (ART) in low- and middle-income countries (LMICs) is of utmost importance to optimize current and future therapeutic strategies for HIV. We sought to ascertain the long-term responses among ART-experienced children and their potential implications. A retrospective, observational, facility-based cohort study was conducted among 136 ART-experienced children monitored for 10 years (2007-2017) at the Essos Hospital Centre in Yaoundé, Cameroon.
View Article and Find Full Text PDFInvestigating the role of nucleoside reverse transcriptase inhibitors in modulating lipotoxicity: Effects on lipid dynamics stress pathways, and insulin resistance on the function of dopaminergic neurons.
Biomed Pharmacother
December 2024
Department of Toxicology, Faculty of Pharmacy, Wroclaw Medical University, Wrocław, Poland.
Despite decades of advancements in HIV treatment, the persistence of viral reservoirs necessitates lifelong therapy, complicating efforts to fully control the infection. Nucleoside reverse transcriptase inhibitors (NRTIs) remain a cornerstone of HIV treatment, but long-term use is associated with side effects, including lipid metabolism disruption and neurocognitive disorders. There is a gap in understanding the safety of antiretrovirals and their impact on lipid toxicity in the central nervous system.
View Article and Find Full Text PDFReverse transcriptase inhibitors in Aicardi-Goutières syndrome: A crossover clinical trial.
Dev Med Child Neurol
December 2024
Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
Aim: To extend the findings of a previous clinical trial suggesting combined abacavir (ABC), lamivudine (3TC), and zidovudine (AZT) reduces type I interferon (IFN) signalling in Aicardi-Goutières syndrome (AGS).
Method: This was an open label, non-placebo-controlled phase II clinical trial (NCT04731103) in patients less than 16 years with any of five AGS genotypes. The effect of ABC or 3TC individually, or of combined ABC + 3TC + AZT, on IFN-stimulated gene (ISG) expression (primary outcome) and IFN-alpha protein (secondary outcome) in blood was assessed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!